HRP20141080T1 - Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina - Google Patents
Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina Download PDFInfo
- Publication number
- HRP20141080T1 HRP20141080T1 HRP20141080AT HRP20141080T HRP20141080T1 HR P20141080 T1 HRP20141080 T1 HR P20141080T1 HR P20141080A T HRP20141080A T HR P20141080AT HR P20141080 T HRP20141080 T HR P20141080T HR P20141080 T1 HRP20141080 T1 HR P20141080T1
- Authority
- HR
- Croatia
- Prior art keywords
- insulin secretagogue
- combination
- glimepiride
- glipizide
- use according
- Prior art date
Links
- 229940122199 Insulin secretagogue Drugs 0.000 title claims 10
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims 6
- 229960004346 glimepiride Drugs 0.000 claims 6
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical group C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 6
- 229960001381 glipizide Drugs 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960004580 glibenclamide Drugs 0.000 claims 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Farmaceutski pripravak naznačen time da sadrži kombinaciju
(A) (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitol ili njegovu farmaceutski prihvatljivu sol, ili hidrat spoja ili njegovu sol; i
(B) sekretagog inzulina.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time da sekretagog inzulina je glipizid, glibenklamid, ili glimepirid.
3. Farmaceutski pripravak prema zahtjevu 2, naznačen time da sekretagog inzulina je glipizid ili glimepirid.
4. Farmaceutski pripravak prema zahtjevu 2, naznačen time da sekretagog inzulina je glipizid.
5. Farmaceutski pripravak prema zahtjevu 2, naznačen time da sekretagog inzulina je glimepirid.
6. Kombinacija:
(A) (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitola ili njegove farmaceutski prihvatljive soli, ili hidrata spoja ili njegove soli; i
(B) ekretagoga inzulina,
naznačena time da je za uporabu u postupku sprečavanja ili liječenja dijabetes melitusa, bolesti povezanih s dijabetes melitusom, ili komplikacija dijabetes melitusa, pri čemu se (A) i (B) daju pacijentu kojem je to potrebno istovremeno ili odvojeno.
7. Kombinacija za uporabu prema zahtjevu 6, naznačena time da sekretagog inzulina je glipizid, glibenklamid, i glimepirid.
8. Kombinacija za uporabu prema zahtjevu 7, naznačena time da sekretagog inzulina je glipizid ili glimepirid.
9. Kombinacija za uporabu prema zahtjevu 7, naznačena time da sekretagog inzulina je glipizid.
10. Kombinacija za uporabu prema zahtjevu 7, naznačena time da sekretagog inzulina je glimepirid.
11. Kombinacija za uporabu prema bilo kojem zahtjevu od 6 do 10, naznačena time da dijabetes melitus je dijabetes tipa 2.
12. Kombinacija za uporabu prema bilo kojem zahtjevu od 6 do 11, naznačena time da komplikacija dijabetes melitusa je dijabetička retinopatija, dijabetička nefropatija, dijabetička neuropatija, cerebrovaskularni poremećaj, ishemijska bolest srca, ili bolest perifernih arterija.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009100210 | 2009-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20141080T1 true HRP20141080T1 (hr) | 2015-01-02 |
Family
ID=42982643
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20131120AT HRP20131120T1 (hr) | 2009-04-16 | 2013-11-25 | Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa |
HRP20141080AT HRP20141080T1 (hr) | 2009-04-16 | 2014-11-05 | Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20131120AT HRP20131120T1 (hr) | 2009-04-16 | 2013-11-25 | Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa |
Country Status (30)
Country | Link |
---|---|
US (1) | US20120040898A1 (hr) |
EP (3) | EP2601949B1 (hr) |
JP (4) | JP5077786B2 (hr) |
KR (2) | KR20150046382A (hr) |
CN (7) | CN102395364A (hr) |
AR (1) | AR076317A1 (hr) |
AU (1) | AU2010237748B2 (hr) |
BR (1) | BRPI1012539A2 (hr) |
CA (1) | CA2755392A1 (hr) |
CY (2) | CY1114703T1 (hr) |
DK (2) | DK2601949T3 (hr) |
ES (2) | ES2523408T3 (hr) |
HK (6) | HK1217301A1 (hr) |
HR (2) | HRP20131120T1 (hr) |
ME (2) | ME02015B (hr) |
MX (1) | MX2011010901A (hr) |
MY (3) | MY156679A (hr) |
NZ (4) | NZ623838A (hr) |
PH (3) | PH12015500235B1 (hr) |
PL (2) | PL2419097T3 (hr) |
PT (2) | PT2601949E (hr) |
RS (2) | RS53761B1 (hr) |
RU (2) | RU2532330C2 (hr) |
SG (6) | SG2014015093A (hr) |
SI (2) | SI2601949T1 (hr) |
SM (1) | SMT201500015B (hr) |
TW (3) | TW201500043A (hr) |
UA (2) | UA105216C2 (hr) |
WO (1) | WO2010119990A1 (hr) |
ZA (1) | ZA201106727B (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
PT2486029E (pt) | 2009-09-30 | 2015-10-14 | Boehringer Ingelheim Int | Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
TR201101809A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
KR102371364B1 (ko) | 2012-05-17 | 2022-03-07 | 브이티브이 테라퓨틱스 엘엘씨 | 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물 |
SG11201501510SA (en) * | 2012-08-30 | 2015-04-29 | Taisho Pharmaceutical Co Ltd | Combinations of sglt2 inhibitors and antihypertensive drugs |
ES2702174T3 (es) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Usos terapéuticos de empagliflozina |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EA033286B1 (ru) | 2013-04-18 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения или отсрочки развития хронической болезни почек |
TW201513857A (zh) * | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | 協同性組成物 |
CN113209295A (zh) * | 2015-02-27 | 2021-08-06 | 财团法人峨山社会福祉财团 | 含有dpp-4抑制剂的用于预防或治疗瓣膜钙化的组合物 |
CN105963280B (zh) * | 2016-06-30 | 2018-11-06 | 合肥华方医药科技有限公司 | 一种伏格列波糖口腔速溶膜及其制备方法 |
JP2019531320A (ja) | 2016-10-19 | 2019-10-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ssao/vap−1阻害剤とsglt2阻害剤とを含む組合せ、その使用 |
EP3540072A4 (en) * | 2016-11-14 | 2020-05-20 | Kaohsiung Medical University | METHOD FOR DETERMINING IF GLUCOSE METABOLISM IS ABNORMAL, AND PREVENTION AND TREATMENT THEREOF |
US20210113561A1 (en) | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
KR20190137343A (ko) | 2018-06-01 | 2019-12-11 | 김유찬 | 계량 인덕션 |
CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
JP2003520759A (ja) | 1999-08-31 | 2003-07-08 | アンドルックス ファーマスーティカルズ インコーポレーテッド | 単位核を有する徐放性錠剤 |
ATE423559T1 (de) * | 2001-04-04 | 2009-03-15 | Ortho Mcneil Janssen Pharm | Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren |
JP2004536047A (ja) * | 2001-04-11 | 2004-12-02 | ブリストル−マイヤーズ スクイブ カンパニー | 糖尿病処置用c−アリールグルコシドのアミノ酸複合体および方法 |
TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
JP5152519B2 (ja) * | 2006-06-29 | 2013-02-27 | 大正製薬株式会社 | C−フェニル1−チオグルシト−ル化合物 |
JP5194588B2 (ja) * | 2006-07-06 | 2013-05-08 | 大正製薬株式会社 | 1−チオ−d−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤 |
US8039441B2 (en) * | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
NZ598778A (en) * | 2006-11-09 | 2013-09-27 | Boehringer Ingelheim Int | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
AU2007332476A1 (en) * | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | 1-phenyl 1-thio-D-glucitol derivative |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
-
2010
- 2010-04-16 KR KR1020157009538A patent/KR20150046382A/ko not_active Application Discontinuation
- 2010-04-16 NZ NZ623838A patent/NZ623838A/en not_active IP Right Cessation
- 2010-04-16 EP EP13157571.4A patent/EP2601949B1/en active Active
- 2010-04-16 SG SG2014015093A patent/SG2014015093A/en unknown
- 2010-04-16 SG SG2011073848A patent/SG175154A1/en unknown
- 2010-04-16 CN CN2010800169522A patent/CN102395364A/zh active Pending
- 2010-04-16 SI SI201030784T patent/SI2601949T1/sl unknown
- 2010-04-16 MX MX2011010901A patent/MX2011010901A/es active IP Right Grant
- 2010-04-16 CN CN201510876678.0A patent/CN105477639A/zh active Pending
- 2010-04-16 WO PCT/JP2010/057196 patent/WO2010119990A1/en active Application Filing
- 2010-04-16 SG SG2014014807A patent/SG2014014807A/en unknown
- 2010-04-16 US US13/264,687 patent/US20120040898A1/en not_active Abandoned
- 2010-04-16 CN CN201510876753.3A patent/CN105434430A/zh active Pending
- 2010-04-16 ME MEP-2015-6A patent/ME02015B/me unknown
- 2010-04-16 JP JP2011540651A patent/JP5077786B2/ja active Active
- 2010-04-16 TW TW103133246A patent/TW201500043A/zh unknown
- 2010-04-16 CN CN201510876739.3A patent/CN105343880A/zh active Pending
- 2010-04-16 ME MEP-2013-137A patent/ME01555B/me unknown
- 2010-04-16 ES ES13157571.4T patent/ES2523408T3/es active Active
- 2010-04-16 EP EP10764570.7A patent/EP2419097B1/en active Active
- 2010-04-16 TW TW099111992A patent/TW201103534A/zh unknown
- 2010-04-16 RU RU2011146335/15A patent/RU2532330C2/ru not_active IP Right Cessation
- 2010-04-16 CN CN201510876708.8A patent/CN105343060A/zh active Pending
- 2010-04-16 RS RS20150042A patent/RS53761B1/en unknown
- 2010-04-16 RS RS20130508A patent/RS53056B/en unknown
- 2010-04-16 NZ NZ710575A patent/NZ710575A/en not_active IP Right Cessation
- 2010-04-16 SG SG2014012405A patent/SG2014012405A/en unknown
- 2010-04-16 DK DK13157571.4T patent/DK2601949T3/da active
- 2010-04-16 PL PL10764570T patent/PL2419097T3/pl unknown
- 2010-04-16 MY MYPI2011004937A patent/MY156679A/en unknown
- 2010-04-16 AU AU2010237748A patent/AU2010237748B2/en not_active Ceased
- 2010-04-16 MY MYPI2015001281A patent/MY183793A/en unknown
- 2010-04-16 KR KR1020117023612A patent/KR20120016051A/ko not_active Application Discontinuation
- 2010-04-16 CN CN201510876636.7A patent/CN105343059A/zh active Pending
- 2010-04-16 PT PT131575714T patent/PT2601949E/pt unknown
- 2010-04-16 PL PL13157571T patent/PL2601949T3/pl unknown
- 2010-04-16 AR ARP100101273A patent/AR076317A1/es unknown
- 2010-04-16 UA UAA201113444A patent/UA105216C2/ru unknown
- 2010-04-16 PT PT107645707T patent/PT2419097E/pt unknown
- 2010-04-16 ES ES10764570T patent/ES2431300T3/es active Active
- 2010-04-16 SG SG2014012553A patent/SG2014012553A/en unknown
- 2010-04-16 TW TW105105937A patent/TW201622720A/zh unknown
- 2010-04-16 CA CA2755392A patent/CA2755392A1/en not_active Abandoned
- 2010-04-16 MY MYPI2015001283A patent/MY182720A/en unknown
- 2010-04-16 NZ NZ595314A patent/NZ595314A/xx unknown
- 2010-04-16 DK DK10764570.7T patent/DK2419097T3/da active
- 2010-04-16 EP EP14183168.5A patent/EP2829271A3/en not_active Withdrawn
- 2010-04-16 SG SG2014012462A patent/SG2014012462A/en unknown
- 2010-04-16 NZ NZ606888A patent/NZ606888A/en not_active IP Right Cessation
- 2010-04-16 BR BRPI1012539A patent/BRPI1012539A2/pt not_active IP Right Cessation
- 2010-04-16 CN CN201510876712.4A patent/CN105343871A/zh active Pending
- 2010-04-16 UA UAA201314870A patent/UA111742C2/uk unknown
- 2010-04-16 SI SI201030365T patent/SI2419097T1/sl unknown
-
2011
- 2011-09-14 ZA ZA2011/06727A patent/ZA201106727B/en unknown
-
2012
- 2012-08-31 JP JP2012191753A patent/JP5660094B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-25 HR HRP20131120AT patent/HRP20131120T1/hr unknown
- 2013-12-05 CY CY20131101103T patent/CY1114703T1/el unknown
-
2014
- 2014-05-26 RU RU2014121260/15A patent/RU2014121260A/ru not_active Application Discontinuation
- 2014-11-05 HR HRP20141080AT patent/HRP20141080T1/hr unknown
- 2014-12-03 JP JP2014245257A patent/JP5910711B2/ja active Active
-
2015
- 2015-01-16 CY CY20151100045T patent/CY1115907T1/el unknown
- 2015-01-19 SM SM201500015T patent/SMT201500015B/xx unknown
- 2015-02-03 PH PH12015500235A patent/PH12015500235B1/en unknown
- 2015-12-25 JP JP2015253932A patent/JP6066144B2/ja active Active
-
2016
- 2016-05-11 HK HK16105348.0A patent/HK1217301A1/zh unknown
- 2016-05-11 HK HK16105353.2A patent/HK1217302A1/zh unknown
- 2016-05-12 HK HK16105415.8A patent/HK1217434A1/zh unknown
- 2016-05-12 HK HK16105417.6A patent/HK1217435A1/zh unknown
- 2016-06-16 HK HK16106920.4A patent/HK1218871A1/zh unknown
- 2016-06-17 HK HK16106970.3A patent/HK1218881A1/zh unknown
-
2019
- 2019-04-30 PH PH12019500959A patent/PH12019500959B1/en unknown
- 2019-04-30 PH PH12019500961A patent/PH12019500961B1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20141080T1 (hr) | Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina | |
HRP20231586T1 (hr) | Agonisti receptora glukagonu sličnog peptida 1 | |
HRP20181025T1 (hr) | Farmaceutski pripravak koji sadrži glp-1-agonist, inzulin, te metionin | |
HRP20151230T1 (hr) | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 | |
HRP20161620T1 (hr) | Uporaba ave0010 za proizvodnju lijeka za liječenje dijabetes melitusa tip 2 | |
JP2008545715A5 (hr) | ||
HRP20151068T1 (hr) | Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2 | |
ES2556466T3 (es) | Lixisenatida y metformina para el tratamiento de la diabetes tipo 2 | |
BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
Karau et al. | Hypoglycemic activity of aqueous and ethylacetate leaf and stem bark extracts of" Pappea capensis" in alloxan-induced diabetic BALB/c mice | |
JP6438944B2 (ja) | インスリングラルギン/リキシセナチド固定比率製剤 | |
HRP20151087T1 (hr) | Prevencija hipoglikemije kod pacijenata s dijabetesom tipa 2 | |
HRP20120948T1 (hr) | Derivati piridina koji su korisni kao aktivatori glukokinaze | |
CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
JP2013525444A5 (hr) | ||
MX2011007371A (es) | Metodo para tratar la hiperglucemia con la molecula. | |
JP2017538705A5 (hr) | ||
EA201792030A1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
JP2018509419A5 (hr) | ||
JP2018503644A5 (hr) | ||
JP2012517459A5 (hr) | ||
CA2750074A1 (en) | Use of cardiotrophin-1 for the treatment of metabolic diseases | |
Mazzucchelli et al. | Comment on Inzucchi et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149 | |
JP2016505628A5 (hr) | ||
CN104056031A (zh) | 一种降血糖的中药保健组合物 |